| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Eli Lilly's focus on innovation is prominently evident through its successful weight-loss products, such as Mounjaro and Zepbound, which have not only driven substantial sales growth but also enhanced the company's market position. The company is investing in manufacturing capacity, indicating a proactive approach to meeting increasing demand. Furthermore, ongoing development in its drug pipeline related to diabetes and obesity treatments reflects a strong commitment to long-term growth. Overall, the company's emphasis on innovative pharmaceutical offerings demonstrates its adaptability within the competitive healthcare landscape. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.6 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.8, and the negative at -0.2 on 2025-11-04. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (4.7) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| LLY | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-04 | 0%(0.1%) | 0 | 0% | 0.6 | 4.7 | 5.3 | |||||||
| 2025-11-03 | 0%(0.1%) | 0 | 0% | 0.6 | 4.8 | -1 | |||||||
| 2025-11-02 | 0%(0.1%) | 0 | 0% | 0.6 | 4.7 | -1 | |||||||
| 2025-11-01 | 0%(0.1%) | 0 | 0% | 0.6 | 4.6 | -1 | |||||||
| 2025-10-31 | 0%(0.1%) | 0 | 0% | 0.6 | 4.4 | 6.5 | |||||||
| 2025-10-30 | 1%(0.1%) | 0 | 0% | 0.6 | 4.4 | 6.8 | |||||||
| 2025-10-29 | 0%(0%) | 0 | 0% | 0.5 | 3.8 | 7 | |||||||
| 2025-10-28 | 0%(0%) | 0 | 0% | 0.4 | 3.5 | 5.5 | |||||||
| 2025-10-27 | 0%(0%) | 0 | 0% | 0.4 | 3.2 | -1 | |||||||
| 2025-10-26 | 0%(0%) | 0 | 0% | 0.4 | 3.2 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-11-04 17:02:25 The notable increase in investor interest towards Eli Lilly indicates a theme of significant monitoring and analysis in stock performance strategies. |
| 2025-11-04 17:02:25 Eli Lilly is mentioned alongside competitors like Pfizer and AbbVie in the context of investment strategies, emphasizing the competitive nature of the medical and pharmaceutical industry. |
| 2025-11-04 17:02:25 The exploration of Eli Lilly's performance and revenue changes in international markets suggests a theme of adapting to global industry trends. |
| 2025-11-04 17:02:25 The negotiation of drug pricing deals with the White House, including the implications for Medicare coverage, highlights concerns and considerations related to regulatory impacts. |
| 2025-11-04 17:02:25 The positive outlook surrounding Eli Lilly's growth, particularly in the context of stock performance and long-term investment potential, is a recurrent theme. |
| 2025-11-04 15:49:07 Market response to news regarding Eli Lilly's obesity drug deal with the government. |
| 2025-11-04 15:49:07 Potential impacts of a government-led initiative on Medicare coverage for obesity drugs. |
| 2025-11-04 15:49:07 The collaboration between Eli Lilly and the White House to provide obesity treatments at a lower cost. |
| 2025-11-04 15:49:07 Discussion around the pricing of obesity medications and its implications for broader access. |
| 2025-11-04 11:59:49 Partnerships between major pharmaceutical companies to address healthcare costs and enhance drug accessibility. |
| 2025-11-04 11:59:49 A rise in shares of Lilly and Novo, indicating investor confidence following news of potential government partnerships. |
| 2025-11-04 11:59:49 Efforts by Lilly and Novo to negotiate lower prices for weight-loss drugs, benefiting consumers and the market. |
| 2025-11-04 11:59:49 The positive impact of new deals with the White House to provide Medicare coverage for weight-loss drugs. |
| 2025-11-04 09:37:06 There is a notable problem that may affect Eli Lilly's growth despite its strong market position. |
| 2025-11-04 09:37:06 Eli Lilly is positioned strongly in a competitive market with a leading role in a new drug category. |